Soumi Gupta

发表

Comparison of Human Immunodeficiency Virus Type 1 Tropism Profiles in Clinical Samples by the Trofile and MT-2 Assays

H. Schuitemaker, C. Petropoulos, A. B. van 't Wout, 2009, Antimicrobial Agents and Chemotherapy.

Combinations of Mutations in the Connection Domain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase: Assessing the Impact on Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitor Resistance

C. Petropoulos, E. Paxinos, E. Stawiski, 2010, Antimicrobial Agents and Chemotherapy.

Virologic Characterization of HIV Type 1 With a Codon 70 Deletion in Reverse Transcriptase

D. Kuritzkes, H. Hatano, Zixin Hu, 2007, Journal of acquired immune deficiency syndromes.

Depletion of interfering IgG and IgM is critical to determine the role of IgE in pegvaliase-associated hypersensitivity.

K. Larimore, R. Zori, H. Weng, 2019, Journal of immunological methods.

Maintenance of long-term immunological memory by low avidity IgM-secreting cells in bone marrow after mucosal immunizations with cholera toxin adjuvant.

Manmohan J. Singh, I. Srivastava, E. Kan, 2004, Vaccine.

Antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles.

P. Luciw, J. Donnelly, C. Greer, 2006, AIDS research and human retroviruses.

Characterization of Human Immunodeficiency Virus Gag-Specific Gamma Interferon-Expressing Cells following Protective Mucosal Immunization with Alphavirus Replicon Particles

P. Luciw, J. Donnelly, C. Greer, 2005, Journal of Virology.

Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria

B. Schweighardt, K. Larimore, B. Burton, 2021, Clinical and translational science.

Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM).

K. Larimore, J. Vockley, D. Dimmock, 2018, Molecular genetics and metabolism.

Vaccination of Cats with Attenuated Feline Immunodeficiency Virus Proviral DNA Vaccine Expressing Gamma Interferon

Soumi Gupta, J. Steckbeck, C. Leutenegger, 2006, Journal of Virology.

β7‐integrin‐independent enhancement of mucosal and systemic anti‐HIV antibody responses following combined mucosal and systemic gene delivery

P. Luciw, J. Donnelly, Manmohan J. Singh, 2007, Immunology.

Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

Christos J. Petropoulos, Wei Huang, D. Hazuda, 2009, Journal of Virology.

Evolution of Integrase Resistance During Failure of Integrase Inhibitor-Based Antiretroviral Therapy

Jeffrey N. Martin, C. Petropoulos, H. Hatano, 2010, Journal of acquired immune deficiency syndromes.

Validation of an IFN-gamma ELISpot assay to measure cellular immune responses against viral antigens in non-human primates

S. Zoog, Fan Yang, Soumi Gupta, 2021, Gene therapy.

Achieving efficacy in subjects with sustained pegvaliase-neutralizing antibody responses.

K. Larimore, S. Zoog, J. Olbertz, 2021, Molecular genetics and metabolism.

The K101P and K103R/V179D Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confer Resistance to Nonnucleoside Reverse Transcriptase Inhibitors

Christos J. Petropoulos, Colombe Chappey, C. Petropoulos, 2006, Antimicrobial Agents and Chemotherapy.

Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials

B. Schweighardt, K. Larimore, J. Atkinson, 2018, EBioMedicine.

Connection Domain Mutations in HIV-1 Reverse Transcriptase Do Not Impact Etravirine Susceptibility and Virologic Responses to Etravirine-Containing Regimens

R. Paredes, B. Clotet, J. Schapiro, 2011, Antimicrobial Agents and Chemotherapy.

Substitutions at Amino Acid Positions 143, 148, and 155 of HIV-1 Integrase Define Distinct Genetic Barriers to Raltegravir Resistance In Vivo

Wei Huang, Christos J. Petropoulos, Arne Frantzell, 2012, Journal of Virology.

Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

D. Hazuda, C. Petropoulos, R. Danovich, 2009, Journal of Virology.